The frontrunners in the COVID-19 vaccine race have emerged with different success rates for their shots in clinical trials, but what does that mean for the global fight against the pandemic?
58mOpinion
Hard-won RTI gains are at risk as privacy legislation tilts the balance against demands of democracy
Two decades after its enactment, India’s ‘sunshine law’ that encodes the Right to Information is losing its power to hold ...
Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...
A research team led by Professor Joshua Rabinowitz of the Department of Chemistry at Princeton University published findings ...
Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...
Korea Hydro & Nuclear Power has simultaneously demonstrated pain relief and functional improvement in a clinical trial using ...
A Pitt faculty member is challenging the effectiveness of shared governance at Pitt, arguing the faculty senate has no real ...
A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.
Companies have built their security strategies around phishing simulations and educational webinars, tactics that research ...
Exclusive IDWeek 2025 coverage on HIV ART regimens, long COVID research, C difficile findings, pneumonia predictors, and more ...
Could a future vaccine against cancer be made better by an immune-boosting virus? Very likely, say Canadian scientists, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback